Gland Pharma Promoters Declare Zero Share Encumbrance for FY26
Shanghai Fosun Pharmaceutical Group and Fosun Pharma Industrial have declared zero share encumbrance for Gland Pharma Limited for FY26 ended 31st March 2026. The SEBI regulatory filing confirms that pledged shares remained at NIL throughout the year, with no direct or indirect encumbrances created on promoter holdings. This declaration reinforces the clean shareholding structure and demonstrates the promoters' financial stability and long-term commitment to the pharmaceutical company.
*this image is generated using AI for illustrative purposes only.
Gland pharma 's promoter group has submitted a regulatory declaration confirming zero share encumbrance for the financial year ended 31st March 2026. The filing, made under SEBI's Substantial Acquisition of Shares and Takeovers Regulations, 2011, reinforces the clean shareholding structure maintained by the pharmaceutical company's promoters.
Promoter Declaration Details
Shanghai Fosun Pharmaceutical Group Co. Ltd and Fosun Pharma Industrial Pte. Ltd, acting as promoters of Gland Pharma Limited, filed the declaration on 02.04.2026. The document was signed by Dorothy Dong, Board Secretary of Shanghai Fosun Pharmaceutical Group Co. Ltd, representing the promoter group and persons acting in concert.
Share Pledging Status
The declaration provides clear confirmation of the promoters' shareholding position throughout FY26:
| Parameter: | Status |
|---|---|
| Shares Pledged (1st April 2025): | NIL |
| Shares Pledged (31st March 2026): | NIL |
| Direct Encumbrance: | None |
| Indirect Encumbrance: | None |
The promoters explicitly stated that they have not created any encumbrance, directly or indirectly, on the shares held by them during the reporting period.
Regulatory Compliance
The filing was made under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. This regulation requires promoters to declare their shareholding and encumbrance status periodically to ensure transparency in corporate ownership structures.
Key regulatory details include:
- Filing Authority: Shanghai Fosun Pharmaceutical Group Co. Ltd
- Reporting Period: FY26 (ended 31st March 2026)
- Declaration Date: 02.04.2026
- Regulatory Framework: SEBI Takeover Regulations
Corporate Governance Significance
The zero encumbrance declaration reflects the promoters' financial stability and commitment to maintaining unencumbered shareholdings in Gland Pharma. This status provides assurance to investors and stakeholders about the promoter group's financial position and their long-term commitment to the pharmaceutical company.
The declaration covers all members of the promoter group and persons acting in concert, ensuring comprehensive disclosure of the ownership structure. This transparency aligns with SEBI's objectives of maintaining fair and transparent capital markets while protecting investor interests.
Historical Stock Returns for Gland Pharma
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.67% | -2.77% | +1.55% | -8.07% | +23.92% | -33.96% |
Will Fosun Pharma consider increasing its stake in Gland Pharma through additional acquisitions in the coming quarters?
How might this clean shareholding structure position Gland Pharma for potential strategic partnerships or joint ventures in the pharmaceutical sector?
Could the zero encumbrance status indicate Fosun's preparation for using Gland Pharma shares as collateral for future expansion financing?
18
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
